Engineered B Cell Receptors for Broadly Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development struggles to create effective vaccines against pathogens like HIV, influenza, Hepatitis C, and Plasmodium falciparum due to their antigenic variability and ability to evade protective antibody responses.
Innovation Solution
Engineering strategies are employed to introduce broadly neutralizing antibody paratopes into B cell receptors, utilizing homology-directed repair (HDR) genome editing to replace immunoglobulin variable regions with selected antibody variable regions, allowing for the generation of protective antibodies against various pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine approaches are used, then the immune system generates antibody responses, but the pathogens (HIV, influenza, Hepatitis C, Plasmodium falciparum) evade these responses due to antigenic variability
Solution Approach 1:
The patent introduces predetermined broadly neutralizing antibody paratopes into B cell receptors before antigen exposure. This preliminary genetic modification ensures that the B cells are pre-equipped with the ability to recognize and neutralize variable antigens, eliminating the need for the immune system to generate these specific responses de novo during natural infection or traditional vaccination.
Solution Approach 2:
The patent fundamentally changes the parameter of antibody specificity by replacing native immunoglobulin variable regions with engineered variable regions that encode broadly neutralizing paratopes. This parameter change transforms the B cell receptor's antigen recognition capability from pathogen-specific to broadly protective across multiple pathogen variants.
2Reliability
If broadly neutralizing antibodies are elicited from the natural repertoire, then protective immunity may be achieved, but these antibodies require rare precursors and extensive hypermutation during affinity maturation
Solution Approach 1:
The patent performs preliminary action by directly introducing the mature, optimized antibody paratopes into B cell receptors, bypassing the entire affinity maturation process. Instead of allowing rare precursors to undergo extensive somatic hypermutation over time, the engineered paratopes are installed directly, achieving the same protective effect immediately without the time loss associated with natural affinity maturation.
Solution Approach 2:
The patent uses copying by transferring the successfully evolved paratopes from previously characterized broadly neutralizing antibodies into the B cell receptor repertoire. Rather than relying on the rare occurrence of similar precursors in the natural repertoire, the proven effective paratopes are copied and introduced directly, eliminating the need for time-consuming de novo affinity maturation.
3Reliability
If B cell receptors are modified to target specific pathogens, then protective immunity is achieved, but the genetic plasticity for affinity maturation and isotype switching must be preserved
Solution Approach 1:
The patent applies segmentation by modifying only the variable region segments of the immunoglobulin genes while leaving the constant regions and regulatory elements intact. This segmented approach allows introduction of new specificity without disrupting the genetic mechanisms responsible for affinity maturation and isotype switching, which are controlled by separate genomic elements.
Solution Approach 2:
The patent achieves universality by designing a modification strategy that simultaneously provides pathogen-specific protection while preserving multiple B cell functions. The engineered B cells maintain the ability to undergo affinity maturation, isotype switching, and long-lived plasma cell differentiation, making the modified B cell receptor system multi-functional rather than single-purpose.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the development of vaccines that can elicit long-lived, self-tolerant, protective antibody responses against a spectrum of diseases, including HIV, by modifying existing Ig loci in B cells while preserving somatic hypermutation and isotype switching functions.
Implementation Method 1
Engineering strategies are employed to introduce broadly neutralizing antibody paratopes into B cell receptors, utilizing homology-directed repair (HDR) genome editing to replace immunoglobulin variable regions with selected antibody variable regions
Implementation Method 2
The new sequences within engineered immunoglobulin loci of the modified cells can be further mutated by Activation-Induced Cytidine Deaminase (AID), to generate variants with altered properties
Implementation Method 3
Variants with improved binding to a given substrate can be selected when expressed on the cell surface using fluorescence activated or magnetic cell sorting (FACS/MACS)
Data Source
AI summary
Methods and systems are described herein for generating engineered B cells with modified immunoglobulin genes. The modified immunoglobulin genes encode modified immunoglobulins that can have high affinity for antigens, including antigens that are variable such the types of antigens on various pathogens that can escape mammalian immune responses.